Skip to content
Open access

GBP6 maintains mitochondrial bioenergetics to promote immune evasion from NK cells in cervical cancer.

Jul 2026 · Cell Reports · Vol 45 8, pp. 117704 · 0 citations · 59 references
Medicine

TL;DR

GBP6 is identified as a mitochondrial regulator linking metabolic fitness to innate immune evasion in cervical cancer and is enriched in high-risk tumors and correlates with poor clinical outcomes.

Abstract

Metabolic reprogramming and immune evasion are central hallmarks of cancer progression; yet, how mitochondrial metabolism shapes immune escape remains unclear. Here, we identify GBP6 as a tumor-intrinsic mitochondrial factor associated with aggressive cervical cancer. GBP6 is enriched in high-risk tumors and correlates with poor clinical outcomes. GBP6 knockdown suppresses tumor cell proliferation and promotes cell death. Mechanistically, GBP6 localizes to mitochondria, interacts with TACO1, and supports respiratory complex IV integrity and activity. GBP6 depletion disrupts mitochondrial bioenergetics, reduces membrane potential and NADPH availability, increases ROS production, and compromises the GSH-GPX4 antioxidant axis, thereby promoting lipid peroxidation and ferroptosis-associated cell death. This mitochondrial redox stress induces ICAM-1 expression through ROS-NF-κB signaling, enhancing NK-cell adhesion, immune synapse formation, and tumor-cell killing. In xenograft models, GBP6 depletion sensitizes tumors to adoptively transferred NK cells. These findings identify GBP6 as a mitochondrial regulator linking metabolic fitness to innate immune evasion in cervical cancer.

Read PDF

Similar papers

Open access Sep 2026

Targeting Mitochondrial Metabolic Reprogramming: Reversing CD8⁺ T Cell Exhaustion and Improving Cancer Immunotherapy Response

This study explores the reversal effect of targeting mitochondrial metabolic reprogramming on CD8⁺ T cell exhaustion within the tumor microenvironment and its synergistic mechanism when combined with immune checkpoint blockade therapy. B16-OVA melanoma and LLC lung cancer tumor-bearing mouse models were established. Us...

Gang Liu, Jia Wang, Alena Mikalaeuna Vasiukevich et al. · 1 citation
Review Sep 2026

Inflammasome-autophagy crosstalk in the tumor microenvironment.

This review integrates traditionally studied pathways into a unified NLRP3-autophagy-mitochondrial stress axis and examines how its stage-, cell-, and context-dependent regulation determines tumor fate.

Pratyasha Mahadani, Sushmita Patra, B. S. Patro et al. · 0 citations
Open access Aug 2026

Kdm2a histone demethylase ablation restores anti-tumor immunogenicity in liver cancer.

KDM2A acts as a key epigenetic regulator of mitochondrial function, genomic stability, and the tumor immune microenvironment in liver cancer, and may enhance tumor immunogenicity and improve responses to immunotherapy, representing a promising therapeutic strategy.

L. Gragnani, M. Lulli, Patrizio Caini et al. · 0 citations
Open access Sep 2026

HDCA suppresses exosomal lncRNA MSTRG171708 release to inhibit Treg-mediated immunometabolism in hepatocellular carcinoma

Hepatocellular carcinoma-mediated regulation of EVs trafficking is established as a critical link between epigenetic modulation and immunometabolic reprogramming, proposing HDCA restoration as a novel therapeutic strategy to impede HCC metastasis.

Feng Yang, Wen-Qiong Huang, Chong-Kai Fang et al. · 0 citations
Open access Sep 2026

Mitochondrial DNA Sensing Reshapes the Tumor Immune Microenvironment via Cooperative cGAS-STING Activation and Ferroptosis

A new mechanism where mtDNA sensing collaborates with ferroptosis via the cGAS-STING pathway to reshape the tumor immune microenvironment is revealed, providing a theoretical basis and potential targets for developing anti-tumor immunotherapies that jointly regulate innate immunity and ferroptosis.

Gang Liu, Jia Wang, Li-Qiang An · 1 citation
Sep 2026

Abstract A116: Mito-Met10 remodels the pancreatic tumor microenvironment through MAVS activation and CD8+ T cell metabolic reprogramming

Pancreatic ductal adenocarcinoma is characterized by an immune-excluded tumor microenvironment that limits responsiveness to immunotherapy. Because mitochondrial metabolism regulates both tumor cell survival and immune cell function, mitochondria-targeted therapies may simultaneously induce tumor cell death and r...

Maria Poimenidou, Mahmoud A. Eid, Joanna Le et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.